Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Merck
AstraZeneca
McKesson

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Patent: 9,764,033

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,764,033
Title:Formulation for anti-.alpha.4.beta.7 antibody
Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-.alpha.4.beta.7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-.alpha.4.beta.7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo.
Inventor(s): Diluzio; Willow (Westford, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Brown; Jason (Burlington, MA), Scholz; Catherine (Woburn, MA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:14/114,832
Patent Claims:see list of patent claims

Details for Patent 9,764,033

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Takeda Pharms Usa ENTYVIO vedolizumab INJECTABLE;INJECTION 125476 001 2014-05-20   Start Trial Millennium Pharmaceuticals, Inc. (Cambridge, MA) 2031-05-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Mallinckrodt
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.